FDA approves new oral drug to relieve constipation from opioid painkillers

Share this article:
Long-term care residents who experience constipation from taking opioids to manage chronic pain may benefit from Amitiza, an oral drug recently approved by the Food and Drug Administration.

Amitiza (lubiprostone) has already been approved in the United States for other conditions, such as constipation-related irritable bowel syndrome. Manufactured by Sucampo Pharmaceuticals Inc./Takeda Pharmaceuticals USA Inc., it is the first oral drug to relieve constipation caused by opioid therapy for managing noncancer pain.

Constipation is a common side effect for people who take oxycodone, fentanyl or other opioids on a long-term basis. Amitiza was approved by the FDA based on 12-week studies of people on these painkillers.

The drug's effectiveness when taken with diphenylheptane opioids, such as methadone, has not been established, according to the manufacturer. The company also warned that lubiprostone should not be taken by anyone with impaired liver function.

Share this article:

More in News

Bulk of Medicaid to be managed care in two years: Avalere

Bulk of Medicaid to be managed care in ...

More than three-quarters of Medicaid beneficiaries will be enrolled in a managed care plan as of 2016, according to an Avalere Health analysis released Thursday. The numbers reveal that managed ...

Nursing home asked for employee's personal information too often, jury rules

The human resources department of a Maine nursing home did not properly protect a former employee's personal identification information, a jury recently ruled.

Test could confirm sepsis within an hour

Nursing home residents might benefit from a new way of diagnosing and treating sepsis made possible by discoveries out of the University of British Columbia.